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For many years, disappointing results have been generated by many investigations, 
which have utilized a variety of immunologic strategies to enhance the ability of a 
patient’s immune system to recognize and eliminate malignant cells. However, in recent 
years, immunotherapy has been used successfully for the treatment of hematologic and 
solid malignancies. The impressive clinical responses observed in many types of cancer 
have convinced even the most skeptical clinical oncologists that a patient’s immune 
system can recognize and reject his tumor if appropriate strategies are implemented. 
The success immunotherapy is due to the development of at least three therapeutic 
strategies. They include tumor-associated antigen (TAA)-specific monoclonal antibod-
ies (mAbs), T  cell checkpoint blockade, and TAA-specific chimeric antigen receptors 
(CARs) T  cell-based immunotherapy. However, the full realization of the therapeutic 
potential of these approaches requires the development of strategies to counteract and 
overcome some limitations. They include off-target toxicity and mechanisms of cancer 
immune evasion, which obstacle the successful clinical application of mAbs and CAR 
T cell-based immunotherapies. Thus, we and others have developed the Fc gamma 
chimeric receptors (Fcγ-CRs)-based strategy. Like CARs, Fcγ-CRs are composed of 
an intracellular tail resulting from the fusion of a co-stimulatory molecule with the T cell 
receptor ζ chain. In contrast, the extracellular CAR single-chain variable fragment (scFv), 
which recognizes the targeted TAA, has been replaced with the extracellular portion 
of the FcγRIIIA (CD16). Fcγ-CR T  cells have a few intriguing features. First, given in 
combination with mAbs, Fcγ-CR T cells mediate anticancer activity in vitro and in vivo 
by an antibody-mediated cellular cytotoxicity mechanism. Second, CD16-CR T  cells 
Abbreviations: ADCC, antibody-dependent cellular cytotoxicity; ADCP, antibody-dependent cellular phagocytosis; ATL, 
adult T  cell leukemia; BC, breast cancer; BLCL, B lymphoblastoid cell line; CAR, chimeric antigen receptor; CCR4, CC 
chemokine receptor 4; CDC, complement-dependent cytotoxicity; CLL, chronic lymphocytic leukemia; CRC, colorectal 
carcinoma; CTL, cytotoxic T cell; DC, dendritic cell; EC, extracellular; EGFR, epidermal growth factor receptor; Fcγ-CR, Fc 
gamma chimeric receptor; FRα, folate receptor alpha; HL, Hodgkin lymphoma; HN, head and neck; IC, intracellular; IFNγ, 
interferon gamma; IgG, immunoglobulin G; IL-12, interleukin-12; IL-15, interleukin-15; mAb, monoclonal antibody; MHC, 
major histocompatibility complex; MM, multiple myeloma; Mog, mogamulizumab; NHL, non-Hodgkin lymphoma; NK, 
natural killer; NSCLC, non-small-cell lung carcinoma; OC, ovarian cancer; PBMC, peripheral blood mononuclear cell; PTCL, 
peripheral T-cell lymphoma; RCC, renal cell carcinoma; scFv, single-chain variable fragment; TAA, tumor-associated antigen; 
TCR, T cell receptor; TGFβ, transforming growth factor beta; TM, transmembrane.
FiguRe 1 | Schematic representation of CD16-CR and classical chimeric antigen receptor molecular structures. The first generation of CR has the 
extracellular domain linked to the intracellular signaling motif of CD3ζ chain while the second generation of CR has an additional co-stimulatory endodomain  
derived from CD28 or 4-1BB linked to the N-terminal of CD3ζ chain.
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can target multiple cancer types provided that TAA-specific mAbs with the appropriate 
specificity are available. Third, the off-target effect of CD16-CR T cells may be controlled 
by withdrawing the mAb administration. The goal of this manuscript was threefold. First, 
we review the current state-of-the-art of preclinical CD16-CR T cell technology. Second, 
we describe its in vitro and in vivo antitumor activity. Finally, we compare the advantages 
and limitations of the CD16-CR T cell technology with those of CAR T cell methodology.
Keywords: antitumor activity, chimeric antigen receptor T  cells, CD16-CR T  cells, CRC, Fc gamma chimeric 
receptor, hematologic malignancies, immunotherapy, solid tumor
In 1989, Gross and colleagues introduced the concept of 
engineering T cells with chimeric receptors capable of overcom-
ing the major histocompatibility complex restriction, laying 
the groundwork to generate a powerful tool for targeted cancer 
immunotherapy (1). The chimeric antigen receptors (CARs) are 
molecules capable of redirecting cytotoxic T cells (CTLs) against 
a tumor-associated antigen (TAA) expressed on the surface of 
malignant cells. A CAR typically consists of a single-chain vari-
able fragment (scFv) derived from the antigen binding region of a 
TAA-specific mAb linked to the T cell receptor (TCR)-associated 
CD3ζ-chain signaling domain (2). This structure refers to the 
first generation of CAR. In vitro and in vivo studies, performed 
using CD3ζ-CARs, showed promising results demonstrating an 
efficient tumor cell elimination. However, the following clinical 
trials failed to confirm the first generation CAR-T cell therapeutic 
efficacy, although a first-generation CAR targeting GD2 induced 
complete remission of neuroblastoma in 3 out of 11 pediatric 
patients (3). These data indicated that a single activating signal 
mediated by the TCRζ chain is not sufficient to obtain a full 
activation of T cells as far as persistence, cytokine release, and 
proliferation is concerned (4, 5). To overcome the first-generation 
CAR-T cell limitations, the co-stimulatory endodomain of CD28 
molecule was added to the intracellular tail of CD3ζ-CARs (6); 
these chimeras were referred to as second generation CARs (7) 
(Figure 1). Second-generation CARs improved T cell functions 
by providing T cells with a stronger signal to avoid T cell anergy 
and apoptosis after antigen binding. The superior activity of the 
second generation over the first generation CARs was demon-
strated in vitro and in vivo models (8, 9). Preclinical data about the 
superiority of second generation CAR over the first generation 
were then corroborated by clinical results (10, 11). In addition, 
there is evidence that the incorporation of CD28 co-stimulatory 
domain into CARs may avoid some of the mechanisms that 
tumor cells utilize to escape from T cells. Indeed, compared to 
the first generation of CAR T cells, (i) CD28-CAR T cells secrete 
higher levels of interferon gamma (IFNγ); (ii) efficiently eradicate 
transforming growth factor beta (TGFβ) producing tumor cells; 
and (iii) suppress TGFβ inhibition of T cell expansion (12, 13).
The enhancement of T  cell activation by the usage of co-
stimulatory molecules, into the first generation of CAR was also 
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described by additional studies in which the CD28 molecule was 
fused in tandem or replaced with 4-1BB (14). Tammana et  al. 
(15) redirected umbilical cord blood T cells to eliminate, in vitro 
and in vivo, both lymphoma and leukemia cells by transducing 
T cells with CD19ζ CAR construct containing CD28 (CD19-28ζ) 
or 4-1BB (CD19-BBζ) or a combination of both (CD19-28BBζ) 
co-stimulatory molecules fused with ζ chain in the intracellular 
domain. They demonstrated that CD19-BBζ CAR T  cells and 
CD19-28BBζ exhibited the highest cytotoxic activity against CD19 
positive leukemia and lymphoma cell lines. Interestingly, treat-
ment with CD19-28BBζ prolonged the survival of lymphoma-
bearing mice to a greater extent than treatment with CD19-BBζ 
CAR T  cells, indicating that 4-1BB molecule enhances the 
co-stimulatory properties of the CD28 molecule in umbilical cord 
blood T  cells. In a second study, Song et  al. (16) assessed the 
impact of 4-1BB co-stimulatory signaling on in vivo persistence, 
tumor localization, and antitumor activity of CAR T  cells in 
epithelial cancer. They constructed two CARs containing a folate 
receptor alpha (FRα) scFv (MOv19) fused with CD3ζ alone 
(MOv19-ζ) or in combination with the 4-1BB co-stimulatory 
domain in tandem (MOv19-BBζ). Both MOv19-ζ and MOv19-
BBζ CAR T cells secreted proinflammatory cytokines and exerted 
cytotoxicity in the presence of FRα positive cancer cells in vitro. 
Remarkably, however, only MOv19-BBζ CAR T cells mediated 
persistent infiltration of the ovarian tumor microenvironment 
leading to tumor regression in immunodeficient mice (16). Thus, 
the availability of a second generation CAR which contained 
a 4-1BB signaling domain resulted in an excellent clinical 
response and prolonged T cell in vivo survival (17). The favorable 
therapeutic results obtained with the dual-signaling CAR T cells 
have prompted investigators to hypothesize that the addition of 
a second co-stimulatory molecule to the CAR would enhance 
T  cells’ antitumor activity. As a result, a third generation CAR 
composed of two distinct co-stimulatory endodomains was 
designed. Different combinations of co-stimulatory proteins 
(e.g. 4-1BB/CD28, CD28/OX40) were assessed, showing various 
effects concerning T cell persistence, cytokine release, and tumor 
regression (15, 18).
More recent investigations aimed to boost the therapeutic 
potential of CAR T cell technology have focused on the develop-
ment of strategies to arm CAR T cells with tools to counteract 
immunosuppression mechanism(s) present in the tumor micro-
environment. Several strategies have been employed to prevent 
CAR T  cell depletion by tumors such as genetic modifications 
to express pro-inflammatory cytokines including interleukin-12 
(IL-12) and interleukin-15, chemokine receptors or co-stimulatory 
ligands (19). CD19-CAR T cells genetically engineered to express 
IL-12 transgene demonstrated improved survival, stronger cyto-
toxic function, and significant resistance to Treg inhibition. Fur-
thermore, they favored modulation of tumor-associated immune 
cells, resulting in high tumor eradication in mouse models (20). 
In the same way, the CD19-CAR T cells genetically engineered 
to express CD40L, a tumor necrosis factor superfamily member, 
displayed enhanced antitumor efficacy against CD40+ cancer 
cells, associated with their ability to affect the tumor phenotype by 
increasing tumor cell sensitivity to Fas-dependent apoptosis and 
immune destruction (21).
The high antitumor activity displayed by adoptive CAR T cell 
transfer, during early clinical trials in B cell malignancies, rep-
resents a point of strength of this technology. In contrast, CAR 
T cell-based immunotherapy has demonstrated a limited efficacy 
with solid tumors. On the other hand, a limitation of this strategy 
is represented by the reported on-target and off-target toxicity 
(22). Side effects as cytokine release syndrome and prolonged 
B-cell depletion were associated with CD19 CAR-T cells infusion 
(23). The extended in vivo persistence of T cell transfer may be 
advantageous as far as anticancer efficacy is concerned but may 
be harmful to the host. Although many strategies have been 
implemented to reduce adverse events, such as the introduction 
of inducible suicide genes (24), interventions aimed to improve 
CAR-T cell safety remain a priority.
Then, additional therapeutic strategies designed to implement 
CAR T  cell functions but capable of controlling their toxicity 
may be underway. One of these strategies involves the Fcγ-CRs 
that are atypical CAR composed of the Fcγ receptor extracel-
lular domain fused to the intracellular signaling motif of CD3ζ  
[Fc gamma chimeric receptor (Fcγ-CR)]. A typical example is the 
extracellular FcγIIIA (CD16)-CR. CD16-CR diverges from the 
typical CAR structure, due to the replacement of the scFv, which 
recognizes the targeted TAA with the extracellular region of the 
CD16. In this context, we will first describe the characteristics of 
CD16-CRs, and then we will discuss their application in tumor 
immunotherapy.
THeRAPeuTiC MONOCLONAL 
ANTiBODieS (mAbs) AND FcγRs
In the last decades, steady progress has been made in human 
can cer treatment with the introduction of therapeutic TAA-
specific mAbs. Rituximab (anti-CD20 mAb), trastuzumab (anti- 
Her2/neu mAb), and cetuximab [anti-epidermal growth factor 
receptor (EGFR) mAb] represent just some examples of mAbs with 
demonstrated efficacy in the treatment of B-cell non-Hodgkin 
lymphoma (NHL), Her2+ breast cancers, colorectal carcinoma, 
and head and neck cancers, respectively (25, 26). Recently, many 
efforts have been made to characterize the mechanisms of action 
that underlie the clinical success of therapeutic TAA-specific 
mAbs. Convincing evidence indicates that mAbs exert their 
antitumor effect by two mechanisms. The first is due to the mAb’s 
ability to interfere with molecular signals involved in malignant 
cell growth and survival, leading to a direct cell death. The second 
is immunologic. It is mediated by antibody-dependent cellular 
cytotoxicity (ADCC) in which mAbs trigger the targeting of 
cancer cells by innate immune effector cells mainly natural killer 
(NK) cells (25) and induce or enhance TAA-specific immunity by 
cognate T cells (27).
The FcγRs are a family of surface proteins composed of 
three classes: FcγRI (CD64), FcγRII (CD32), and FcγRIII 
(CD16) with similar structures but distinct functions. They are 
widely distributed on the surface of immune cells like NK cells, 
mono cytes, macrophages, dendritic cells (DCs), and B  cells 
(28). When the antibody engages the CD16 on NK  cells, it 
triggers downstream activating pathways resulting in perforin/
granzyme-dependent tumor target cell lysis (29). Several lines of 
TABLe 2 | Summary of published preclinical studies involving CD16-CR-engineered T cell-based immunotherapy.
CD16-CRs Structure Malignant cells Associated monoclonal 
antibody
Reference
CD16/γ CD16 (EC) + FcεRIγ [transmembrane (TM), IC] B-lymphoblastoid Rituximab Clémenceau et al. (35)
CD16ζ CD16(EC) + CD3ζ (TM, IC) CD20+ lymphoma, HER2/neu+  
breast cancer, and T cell leukemia
Rituximab Ochi et al. (36)
Trastuzumab
Mogamulizumab
CD16V-BB-ζ CD16(EC) + CD8a (TM) + 4-1BB + CD3ζ (IC) CD20+, primary B chronic lymphocytic 
leukemia, neuroblastoma
Rituximab Kudo et al. (37)
Hu14.198K322A
CD16-28-ζ CD16(EC) + CD8a (TM) + CD28 + CD3ζ (IC) Burkitt’s lymphoma Rituximab D’Aloia et al. (38)
TABLe 1 | Summary of therapeutic monoclonal antibodies (mAbs) with proved antibody-dependent cellular cytotoxicity (ADCC) activity.
Name Target disease Target antigen immunoglobulin  
g (igg) subclasses
Type
Rituximab (Rituxan) Non-Hodgkin lymphoma (NHL) CD20 IgG1 Chimeric
Ofatumumab (Arzerra) Chronic lymphocytic leukemia (CLL) CD20 IgG1 Human
Ocaratuzumab CLL CD20 IgG1 Humanized
Tositumomab (Bexxar) NHL CD20 IgG2 Murine
Lucatumumab Relapsed CLL CD40 IgG1 Murine
Multiple myeloma (MM), NHL, and HL
Daratumumab (Darzalex) MM CD38 IgG1 Human
Alemtuzumab (Campath-1H) CLL CD52 IgG1 Humanized
Cetuximab (Erbitux) Squamous cell carcinoma Epidermal growth factor  
receptor (EGFR)
IgG1 Chimeric
CRC
Panitumumab (Vectibix) CRC EGFR IgG2a Human
Trastuzumab (Herceptin) BC ErbB2 IgG1 Humanized
HER2+
Avelumab Bladder cancer, gastric cancer, mesothelioma, non- 
small-cell lung carcinoma, ovarian cancer, head and  
neck cancer, renal cell carcinoma
PDL-1 IgG1 Human
Mogamulizumab Adult T cell leukemia, peripheral T-cell lymphoma CC chemokine receptor 4 IgG1 Humanized
aAn IgG2 subclass of mAb capable of mediating ADCC by myeloid cells only.
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evidence suggest the involvement of the FcγRs in the antitumor 
activity of therapeutic mAbs. They include the lower antitumor 
activity of rituximab and trastuzumab in mice lacking FcγR 
compared to wild-type mice (30), and the association between 
CD16 genetic polymorphism with patients’ clinical responses to 
mAb treatment observed in some malignant diseases (31, 32). 
Notably, the presence of CD16 158-valine allelic polymorphism 
predicted a better clinical response to rituximab treatment in 
NHL patients and an improved clinical outcome in colorectal 
carcinoma patients treated with cetuximab (32). So, evidence 
coming both from preclinical and clinical studies underlie the 
high impact of ADCC and FcγRs on mAb anticancer activity. A 
list of the therapeutic mAbs with demonstrated ADCC activity 
is reported in Table 1.
The ADCC-mediated clinical success of mAbs is influenced 
not only by the CD16 allotypes but also by tumor accessibility 
to cytotoxic cells. In some cases, the tissue architecture may be 
difficult to reach by the ADCC effector cells such as NK  cells, 
which poorly infiltrate tumor microenvironment (33). In these 
cases, the ADCC-mediated anticancer activity of mAbs is reduced. 
A novel approach useful to overcome this NK  cell limitation 
and to enhance mAbs’ cell-mediated cytotoxicity utilizes Fcγ- 
CR-engineered T  cells since CTLs easily infiltrate the tumor 
microenvironment and their presence is closely associated with 
a favorable course of the disease in many types of cancers (34).
CD16-CRs
Two generations of CD16-CRs have been reported (35–38) 
(Figure 1). T cells transduced with CD16-CR display antitumor 
activity only when they are combined with mAbs. Preclinical 
studies have demonstrated that CD16-CRs trigger cell-mediated 
cytotoxicity against lymphoma cell lines opsonized with the 
CD20-specific mAb, rituximab. However, no clinical trials have 
been conducted to date (Table 2). CD16-CR T cells share with 
CAR T cells advantages and disadvantages. The former include 
the ability to mediate an HLA-unrestricted cell-mediated cyto-
toxicity leading to the elimination of cancer cells with abnor-
malities in HLA-class I antigen processing machinery component 
expression and/or function. The latter involve the targeting of a 
TAA also expressed in normal tissues. However, this atypical 
CAR brings also three additional advantages compared to clas-
sical CARs, although not yet demonstrated. The first one is the 
possibility to target different types of tumor cells provided that 
the TAA-specific mAb with the required specificity are available 
(Figure 2). The second one is the possibility to improve control 
of their off-target toxicity, simply by eliminating the supply of 
mAbs to CD16-CR T  cells through mAb dosage tapering or 
termination during patient treatment. The third one is the 
opportunity to mitigate acute toxicity by the administration of 
high-doses of immunoglobulins. On the other hand, CD16-CR 
FiguRe 2 | Therapeutic monoclonal antibodies (mAbs) confer to 
CD16-CR T cells multiple target specificities. (A) The ability of chimeric 
antigen receptor (CAR) to redirect T cells toward tumor cells is restricted to  
a single tumor-associated antigen (TAA) expressed on tumor cell surface.  
(B) The availability of therapeutic mAbs allows CD16-CR to redirect T cells 
virtually against all TAA expressed on a variety tumor types including 
hematological and epithelial malignancies.
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T cells bear additional limitations since therapeutic mAbs may 
compete with serum immunoglobulins for their binding to 
the Fcγ CRs and may be defective in their ability to mediate 
ADCC. Other potential disadvantages of Fcγ-CR T  cells could 
be hypothesized when these cells are given to patients with high 
levels of autoantibodies or viral-specific antibodies following 
an infectious episode. In the course of autoimmunity, autoanti-
bodies may redirect engineered T cells against self-antigens. In 
contrast during an infectious episode, specific-antivirus antibod-
ies could redirect the virus toward engineered T cells, by the Fc 
fragments, favoring a viral infection of the cells, which may lead 
to T cell aberration (39).
FiRST geNeRATiON OF CD16-CR
With the goal to utilize cell-mediated cytotoxicity as a mechanism 
to potentiate the anticancer activity of TAA-specific mAb, Clé-
menceau and colleagues (35) proposed to engineer T lymphocytes 
with the first generation of a CD16-CR. They developed a fusion 
protein composed of the extracellular domain of CD16 ligated 
to the transmembrane (TM) and the intracellular domain of 
FcεRIγ (CD16/γ). This construct was utilized to transduce TCRαβ 
CD4+ and CD8+ HLA-DPB1*0401-specific T cells. The cytotoxic 
activity of the CD16/γ-T cells was demonstrated in vitro against 
HLA-DPB1*0401-positive, and negative B-lymphoblastoid cell 
lines opsonized with rituximab. Target cell lysis was detected 
neither with non-transduced T  cells against HLA-DPB1*0401-
negative cell lines nor with CD16/γ-transduced T cells without 
rituximab. Conversely, in the presence of rituximab, both 
HLA-DPB1*0401-positive and negative cell lines were killed at a 
similar level by transduced T lymphocytes. Overall, these results 
indicated the ability of the CD16/γ receptor to trigger T cell cyto-
toxicity against mAb-opsonized target cells without prior TCR 
recognition. Furthermore, transduced T cell clones showed active 
proliferation and cytokine release upon CD16 crosslinking by 
mAb-coated target cells. Epstein–Barr virus-specific CTLs were 
also transduced with the CD16/γ-CR and were used to confirm 
that CD16/γ-CR expression confers the ability to mediate ADCC 
both to CD4+ and CD8+ T cells.
The in vitro characterization of the CD16/γ -T cells performed 
by Clémenceau et  al. (35) for the first time demonstrated the 
possibility to transfer the ADCC capacity to T  cells. With a 
similar purpose, later Ochi and collaborators (36) proposed a 
variant of the CD16-CR obtained by linking the CD16 with the 
TM and the intracellular portion of CD3ζ (CD16ζ). The chimeric 
receptor was successfully expressed by lentiviral transduction on 
T cell surface of a healthy donor, and ADCC activity was reported 
against CD20+ lymphoma, Her2/neu+ breast cancer and T-cell 
leukemia cell lines coated with rituximab, trastuzumab, and 
mogamulizumab (Mog), respectively. The tumoricidal activity of 
CD16ζ T cells was increased by enhancing the dose of the mAb and 
was blocked by a CD16-specific mAb termed 3G8. Following the 
CD16ζ engagement by the mAb-opsonized cancer cells, CD16ζ-
transduced T cells displayed several functional activities such as 
IFNγ and IL-2 secretion, lytic granule release, and pro liferation. 
Furthermore, Ochi and colleagues assessed the antitumor acti-
vity of the CD16ζ T cells generated through the transduction of 
peripheral blood mononuclear cells harvested from CD20+ B-cell 
lymphoma patients. They found that CD16/γ-T cells exerted anti-
tumor activity against autologous tumor cells to the same extent 
of healthy donors’ transduced T cells.
The antitumor efficacy of CD16ζ T cells combined with the 
specific therapeutic mAb was also validated in  vivo. A tumor 
growth inhibition was reported in B-cell lymphomas immuno-
deficient xenografted murine model when mice were treated with 
a combination of rituximab and CD16ζ T cells. Conversely, no 
significant tumor mass reduction was observed in mice treated 
with CD16ζ T  cells or rituximab alone compared to untreated 
animals. The overall survival reflected the same pattern: the 
regimen of CD16ζ T  cells plus rituximab prolonged mice sur-
vival to a significantly greater extent than other treatments. The 
authors emphasized that CD16ζ T cells have a better in vivo anti-
lymphoma activity than NK cells (36).
Recently, an anti-adult T cell leukemia (ATL) effect has also 
been reported utilizing CD16ζ T cells in association with Mog, 
an anti-CC chemokine receptor 4 mAb (40). T cells deriving both 
from healthy donors and ATL patients armed with CD16ζ-CR 
exerted a significant ADCC against Mog-coated leukemia cell 
lines and ATL primary cells. Furthermore, the simultaneous infu-
sion of Mog and CD16ζ T cells in ATL xenografted mouse models 
significantly blocked tumor spread and prolonged mice survival.
Despite the encouraging preclinical results obtained both 
with the CD16/γ and the CD16ζ first-generation CRs, no clinical 
trials have been conducted yet.
SeCOND geNeRATiON OF CD16-CR
The second generation of CD16-CR was described both by Kudo 
et  al. (37) and by D’Aloia et  al. (38). Kudo et  al. generated the 
CD16V-BB-ζ-CR by introducing the TM portion of CD8a and 
the co-stimulatory endodomain of the 4-1BB into the module 
of the first-generation CD16ζ-CR (37). After CD16V-BB-ζ 
FiguRe 3 | Mechanisms of CD16-CR T cell-mediated tumor cell 
elimination. CD16-CR T cells acquire the specificity of a monoclonal 
antibody (mAb) recognizing a tumor-associated antigen (TAA) on the cell 
surface of tumor cells through the binding of the CD16 with the mAb Fc 
fragment leading to the activation of T cell-mediated cytotoxicity. In this 
context, engineered T cells kill tumor cells by using two mechanisms.  
The first involves the activation of T cell killing machinery by the release  
of cytotoxic granules (upper panel). The second arises from the induction  
of CD16-CR dependent FAS expression on the cell surface of tumor cells 
that allows FAS ligand positive-engineered T cells to kill tumor cells by a 
granule independent cellular cytotoxicity (lower panel). However, the latter 
mechanism is just a hypothetical model based on a single study employing 
transformed MD45 mouse T cells. Then, the confirmation of the existence  
of a role for granule independent cytotoxicity requires additional studies.
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transduction into T  cells, they investigated the capacity of the 
CD16-CRs to induce T cell functional activation upon a CD16 
receptor crosslinking by an immobilized IgG. They found that 
CD16V-BB-ζ engagement promoted IL-2 receptor expression 
and exocytosis of cytotoxic granules by T  lymphocytes. The 
T  cells expressing CD16V-BB-ζ -CR were able to mediate 
 granule-dependent ADCC toward CD20+ cell lines and primary 
B chronic lymphocytic leukemia cells. About 50–70% of the target 
cells were killed in a 4-h co-culture test. The anticancer efficacy 
of the CD16V-BB-ζ T cells, in the presence of the specific thera-
peutic mAbs, was also demonstrated against solid tumors such 
as breast and gastric cancer cell lines. Furthermore, the authors 
validated the tumor regression capacity of the CD16V-BB-ζ 
T cells in NOD-SCID IL-2RGnull mice injected with B-cell lym-
phoma. In all five mice treated with rituximab combined with 
CD16V-BB-ζ T cells, a stable remission of the tumor mass was 
observed after 120 days from the injection. Similar results were 
reported against xenografted neuroblastoma murine model when 
hu14.198K322A mAb was used with CD16V-BB-ζ T cells.
Furthermore, Kudo et  al. compared the CD16V-BB-ζ-CR 
with the CD16/γ, CD16ζ-CRs, and CD19-CAR demonstrating a 
superior T cell activation capacity and antitumor activity of the 
CD16V-BB-ζ (37). They also compared the CD16V-BB-ζ T cells 
with T cells transduced with a typical CD19-CAR (CD19-BB-ζ) 
regarding cytotoxic effects. They found that target cell elimination 
was higher with CD16V-BB-ζ-CR than with CD19-CAR T cells.
While Kudo et al. highlighted the ADCC-mediated antitumor 
efficacy of the CD16-CR with the co-stimulatory domain of 
4-1BB, D’Aloia et al. investigated the ability of a CD16-CR variant 
carrying the CD28 co-stimulatory motif (CD16-28-ζ) (38). They 
assessed the functionality of the CD16-CR in the MD45 cell line, 
a murine T cell hybridoma lacking the lytic granule machinery 
but with cell killing ability through the Fas/FasL pathway. First, 
they proved the ability of this chimera to induce MD45 cell 
activation upon the IgG binding, showing the phosphatidylino-
sitol-3-kinase phosphorylation and IL-2 secretion. The perforin/
granzyme deficient MD45 cell line allowed to test the capacity 
of CD16-CR to trigger tumor cell depletion by the mediation of 
Fas/FasL pathway. A 16-h cytotoxicity assay performed with Fas+ 
Raji lymphoma cells as target cells demonstrated that about 30% 
of the tumor cells were lysed by the effector cells, at the highest 
effector: target ratio, only in the presence of rituximab. A better 
result regarding the percentage of target cell lysis was reported 
redirecting MD45-CD16-CR against P815 cells with B73.1, an 
anti-CD16 mAb, demonstrating that CD16-CR was able to trig-
ger both ADCC and reverse ADCC. Interestingly, the elimination 
of rituximab-coated Raji cells by MD45-CD16-CR cells was 
abrogated by an anti-FasL mAb. These results strongly suggest 
that a Fas/FasL-mediated killing is involved (Figure 3).
FuTuRe PeRSPeCTiveS FOR FC-
gAMMA-CR T CeLLS
CD16-CR T  cells utilized in combination with TAA-specific 
mAbs have provided clear evidence of antitumor activity toward 
hematologic and epithelial malignant cells in vitro and in vivo. 
The mechanisms by which CD16-CR T cells, in combination with 
mAbs, eliminate cancer cells involve both granule-dependent 
and granule independent cellular cytotoxicity. This information 
represents a platform for developing Fcγ-CR-based targeted 
therapies of virtually any malignancies, as long as therapeutic 
mAbs with the appropriate specificity are available. To reach this 
goal, additional information is needed to optimize Fcγ-CR and 
mAb combination before testing the described strategy in a clini-
cal setting. To this end, investigators will need to accomplish three 
primary tasks. The first task will be aimed to identify strategies 
that will increase the pool of therapeutic mAbs capable of redi-
recting T cells against cancer cells. The second task should have 
the objective to determine the best solid tumor to be targeted. 
The third task should determine in vivo toxicity of Fcγ-CR-based 
immunotherapy.
In this context, it is critical to consider the basis of the 
interaction of therapeutic mAbs with Fc receptors. The isotype 
IgG1 is the prevalent subclass of IgG mAbs utilized in the clinic 
(Table 1). IgG1 mAbs preferentially bind CD16valine-158-valine but also 
CD16valine-158-phenylalanine variants. They are capable of triggering 
NK  cell and monocyte-mediated ADCC but also antibody-
dependent cellular phagocytosis, and complement-dependent 
cytotoxicity. In contrast, IgG2 is also used in mAb therapeutics; 
however, it elicits significant weaker ADCC since it does not trigger 
NK cell-mediated cytotoxicity, as compared to IgG1. Nevertheless, 
they are still capable of eliciting a myeloid cell-mediated cytotox-
icity (41). As a consequence, the use of IgG2 therapeutic mAbs in 
EGFR positive malignancies, and particularly in those with KRAS 
mutations, may trigger lower antitumor activity than IgG1 mAbs. 
Interestingly, most subclasses of monomeric mAbs including 
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IgG1, IgG3, and IgG4 but not IgG2 display a high-affinity Fc 
binding to the FcγRI (CD64) leading to the stimulation of a potent 
myeloid-mediated cytotoxicity and phagocytosis. Unfortunately, 
CD64-mediated ADCC may have a limited impact on the inhi-
bition of tumor progression since it does not involve NK cells. 
Given the availability of four IgG2 and three IgG4 therapeutic 
mAbs, it is likely that investigators will maximize the antitumor 
effect of the therapeutic mAb of interest by engineering T cells 
with the most appropriated Fcγ-CR. Since, the CD16-CR is the 
only molecule today available in the laboratories, in order to 
identify the best combination of therapeutic mAb with Fcγ-CR, 
there will be a need for developing the CD32 and CD64 CRs to be 
utilized in additional studies in vitro and in vivo.
It is noteworthy that solid tumors are not an ideal target for 
immune cells. This is mainly due to the ability of cancer cells to 
avoid immune cells by utilizing several types of escape mecha-
nisms affecting accessibility, persistence, and function of immune 
cells in the tumor microenvironment. Compelling evidence sug-
gests that solid tumors do not promote an efficient ADCC since 
their microenvironment is deficient in NK cells (42) but rich in 
M2 macrophages endowed with immunosuppressive and pro-
angiogenic functions (43) and regulatory T cells (44). As a con-
sequence, such an anti-inflammatory microenvironment favors 
tumor progression. Nevertheless, colorectal carcinoma (CRC) 
represents an interesting exception. Among solid tumors, immune 
cell infiltration in the CRC microenvironment is associated 
with improved overall survival even in the presence of known 
immunosuppressive cells such as tumor-associated macrophages 
(45, 46), and regulatory T  cells (44). In addition, two lines of 
evidence suggest that ADCC contributes to the antitumor activity 
of anti-EGFR mAbs. First, a subset of CRC cells is consistently 
infiltrated by NK cells (47, 48). Second, the presence of a CD16valine-
158-valine predicts favorable clinical responses in CRC patients (32). 
Based on this information in our opinion, CRC could be an ideal 
target for assessing the antitumor activity of Fcγ-CR T cells.
Finally, to determine the potential toxicity of this treatment, 
it may be useful to utilize immunocompetent mice bearing a 
spontaneous or engrafted CRC to be targeted with mouse Fcγ-CR 
T cells in combination with mouse anti-EGFRs mAbs.
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